Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited has informed shareholders about its 42nd Annual General Meeting and related shareholder communication. The AGM will be held on July 23, 2026 at 11:00 a.m. IST through video conferencing and other audio-visual means.
The company’s Notice and Integrated Annual Report for financial year 2025-26 are available online via a provided web link and QR code, and letters are being sent to shareholders without registered email addresses. The board has proposed a final dividend of ₹8 per equity share, with a record date of July 10, 2026 and payment on or before July 30, 2026.
The filing also provides e-voting details, with eligibility set by a cut-off date of July 16, 2026 and remote e-voting available from July 19 to July 22, 2026. Shareholders are requested to update their KYC details with their depository participants or the company’s registrar and transfer agent, and contact details for the registrar are provided for queries and service requests.
Dr. Reddy’s Laboratories Limited reports that the United States Food & Drug Administration has completed a Pre-License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection, conducted from June 16 to June 25, 2026, resulted in a Form 483 with seven observations.
The company states it will address these observations within the stipulated timeline. This update follows earlier inspections and related disclosures made to stock exchanges on October 12, 2023 and September 13, 2025, and is provided for information of investors and exchanges.
Dr. Reddy’s Laboratories Limited has scheduled a Board meeting for July 22, 2026 to consider the company’s unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The company also announced that its trading window for dealing in its securities will be closed from June 24, 2026 to July 24, 2026, in line with insider trading regulations.
Dr. Reddy’s Laboratories Limited submitted a Form 6-K providing an intimation to multiple stock exchanges about shareholder communications. The company enclosed copies of newspaper advertisements titled “Notice of the 42nd Annual General Meeting to be held through video conference, record date and final dividend information,” published in Business Standard and Nava Telangana. The same communication was also emailed to all shareholders, ensuring broad circulation of details about the upcoming annual general meeting and related dividend information.
Dr. Reddy’s Laboratories Limited reported a routine employee stock option exercise. The company allotted 6,730 equity shares of Re.1 each on June 19, 2026 to eligible employees under its 2002 Employee Stock Option Scheme and 2007 Employees ADR Stock Option Scheme.
The allotment covers 2,455 shares at an exercise price of Re.1, 2,000 shares at Rs. 562.80, and 2,275 shares at Rs. 735.80. After this issue, total issued shares are 83,46,76,800 and total issued share capital is Rs. 83,46,76,800, with paid-up capital of 83,46,75,800 equity shares of Re.1 each.
Dr. Reddy’s Laboratories has announced the first-to-market U.S. launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, expanding its oncology portfolio and focus on affordable cancer care. The product is a first-to-file generic and is eligible for 180 days of generic drug exclusivity for the 400mg strength in the United States.
Dr. Reddy’s holds exclusive marketing rights in the U.S., while MSN Laboratories developed and manufactures the product. The Bosulif 400mg brand recorded approximately $253.8 million in U.S. sales for the 12 months ended April 2026, highlighting the commercial potential of this oncology therapy launch.